drugset / Trial / NCT01313845
Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease
Phase 4
Completed
46 enrolled
Jee-Young Lee
Hanyang University · collabSamsung Medical Center · collabSeoul National University Boramae Hospital · collabSeoul National University Bundang Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A double-blinded randomized placebo-controlled trial of intravenous amantadine on gait freezing refractory to oral anti-parkinsonian medications in patients with Parkinson's disease. * administration of IV amantadine or normal saline for 5 days, 2 times a day while keeping current oral anti-parkinsonian medications unchanged * follow-up after administration of IV amantadine for 4 weeks * allocation ratio of amantadine:normal saline is 2:1
Timeline
- Start
- 2011-02
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amantadine | Unknown | 100 mg | Intravenous |